Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03379051
Title Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors TG Therapeutics, Inc.

chronic lymphocytic leukemia


Ublituximab + Umbralisib + Venetoclax

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.